Table 3

Dactylitis MRI total and partial scores

Dactylitis total scoreBaselineWeek 24
Population
(n=36)
GLM+MTX
(n=18)
PLB+MTX
(n=18)
P value* Population
(n=36)
GLM+MTX
(n=18)
PLB+MTX
(n=18)
P value Median change
GLM+MTX
Median change
PLB+MTX
P value
Median (IQR)8 (7)8.5 (7)8.0 (10)0.6963.5 (4)2 (3)5.5 (3)0.017−5.5 (4.8)−3.5 (6.5)0.273
(observed range)2 to 202 to 172 to 200 to 170 to 170 to 7−14 to 0−13 to 2
Dactylitis partial scoresMCP/MTPPIPDIP
GLM+MTXPLB+MTXGLM+MTXPLB+MTXGLM+MTXPLB+MTX
BaselineChangeBaselineChangeBaselineChangeBaselineChangeBaselineChangeBaselineChange
Synovitis, mean0.56−0.280.78−0.170.78−0.61* 0.5−0.220.38−0.310.310.12
(observed range)(0 to 1)(−1 to 1)(0 to 1)(−1 to 0)(0 to 1)(−1 to 0)(0 to 1)(−1 to 0)(0 to 1)(−1 to 0)(0 to 1)(0 to 1)
Bone oedema, mean0.44−0.280.5−0.390.67−0.56§ 0.44−0.220.31−0.230.38−0.06
(observed range)(0 to 1)(−1 to 0)(0 to 1)(−1 to 1)(0 to 1)(−1 to 0)(0 to 1)(−1 to 0)(0 to 1)(−1 to 0)(0 to 1)(−1 to 0)
Subcutaneous oedema, mean0.5−0.440.67−0.390.78−0.610.5−0.330.38−0.310.5−0.12
(observed range)(0 to 1)(−1 to 0)(0 to 1)(−1 to 0)(0 to 1)(−1 to 0)(0 to 1)(−1 to 0)(0 to 1)(−1 to 0)(0 to 1)(-1 to 1)
Flexor tenosynovitis, mean0.33−0.220.56−0.170.44−0.220.44−0.170.23−0.080.25−0.19
(observed range)(0 to 1)(−1 to 1)(0 to 1)(−1 to 1)(0 to 1)(−1 to 0)(0 to 1)(−1 to 1)(0 to 1)(−1 to 0)(0 to 1)(−1 to 0)
Extensor paratenonitis, mean000.11−0.1100.060.11−0.110.15−0.080.06−0.06
(observed range)(0 to 0)(0 to 0)(0 to 1)(−1 to 0)(0 to 0)(0 to 1)(0 to 1)(−1 to 0)(0 to 1)(−1 to 0)(0 to 1)(−1 to 0)
Volar and palmar/plantar plate enhancement, mean0.5−0.330.59−0.470.5−0.440.44−0.280.23−0.150.31−0.12
(observed range)(0 to 1)(−1 to 1)(0 to 1)(−1 to 0)(0 to 1)(−1 to 0)(0 to 1)(−1 to 0)(0 to 1)(−1 to 0)(0 to 1)(−1 to 1)
Collateral ligament enhancement, mean0.39−0.280.67−0.330.39−0.280.44−0.280.23−0.150.38−0.12
(observed range)(0 to 1)(−1 to 0)(0 to 1)(−1 to 0)(0 to 1)(−1 to 0)(0 to 1)(−1 to 0)(0 to 1)(−1 to 0)(0 to 1)(−1 to 0)
Erosions, mean0.3900.4400.61−0.060.2800.3100.50
(observed range)(0 to 1)(−1 to 1)(0 to 1)(0 to 0)(0 to 1)(−1 to 0)(0 to 1)(0 to 0)(0 to 1)(0 to 0)(0 to 1)(0 to 0)
  • *Differences in the dactylitis total score at baseline, between treatment arms.

  • †Differences in the dactylitis total score at week 24, between treatment arms.

  • ‡Differences in the median change of the dactylitis total score from baseline to week 24, between treatment arms.

  • §Differences in the mean change of the dactylitis partial score from baseline to week 24, between treatment arms. p<0.05.

  • DIP, distal interphalangeal joints; GLM, golimumab; MCP/MTP, metacarpal/metatarsophalangeal joints; MTX, methotrexate; PIP, proximal interphalangeal joints; PLB, placebo.